New drug duo battles tough head & neck cancers
NCT ID NCT05523323
Summary
This completed Phase 3 trial tested whether adding the drug lenvatinib to the immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced head and neck cancer that has returned or spread. It involved 112 participants whose cancer had a specific marker (PD-L1). The main goals were to see if the combination helped patients live longer, slowed cancer growth, and shrank tumors more effectively.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anhui Cancer Hospital-Radiology Department ( Site 3333)
Hefei, Anhui, 230031, China
-
Beijing Cancer Hospital ( Site 3314)
Beining, Beijing Municipality, 100036, China
-
Beijing Tongren Hospital affiliated to Capital Medical University ( Site 3343)
Beijing, Beijing Municipality, 100730, China
-
Changzhou Tumor Hospital - Changzhou Fourth People's Hospital ( Site 3339)
Changzhou, Jiangsu, 213000, China
-
Chongqing Cancer Hospital ( Site 3327)
Chongqing, Chongqing Municipality, 400030, China
-
Fudan University Shanghai Cancer Center ( Site 3324)
Shanghai, Shanghai Municipality, 200032, China
-
Fujian Provincial Cancer Hospital ( Site 3326)
Fuzhou, Fujian, 350014, China
-
Guangxi Medical University Affiliated Tumor Hospital ( Site 3322)
Nanning, Guangxi, 530000, China
-
Guizhou Cancer Hospital ( Site 3330)
Guiyang, Guizhou, 550003, China
-
Henan Cancer Hospital ( Site 3309)
Zhengzhou, Henan, 450008, China
-
Hunan Cancer Hospital ( Site 3311)
Changsha, Hunan, 410000, China
-
Hunan Cancer Hospital ( Site 3334)
Changsha, Hunan, 410013, China
-
Jiangxi Cancer Hospital ( Site 3313)
Nanchang, Jiangxi, 330029, China
-
Jilin Cancer Hospital ( Site 3310)
Changchun, Jilin, 130000, China
-
Peking Union Medical College Hospital ( Site 3304)
Bejiing, Beijing Municipality, 100032, China
-
Shanghai 9th People hospital ( Site 3332)
Shanghai, Shanghai Municipality, 200011, China
-
Shanghai East Hospital ( Site 3300)
Shanghai, Shanghai Municipality, 200120, China
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University ( Site 3336)
Guangzhou, Guangdong, 510000, China
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University ( Site 3338)
Guangzhou, Guangdong, 510000, China
-
The First Affiliated Hospital of Xi an Jiaotong University ( Site 3328)
Xi'an, Shaanxi, 710000, China
-
The First Affiliated Hospital, Sun Yat-sen University ( Site 3344)
Guangzhou, Guangdong, 510080, China
-
The Third Affiliated Hospital of Harbin Medical University ( Site 3302)
Harbin, Heilongjiang, 150081, China
-
Tianjin Medical University Cancer Hospital ( Site 3312)
Tianjin, Tianjin Municipality, 300060, China
-
Tongji Hospital Tongji Medical,Science & Technology ( Site 3316)
Wuhan, Hubei, 430030, China
-
West China Hospital of Sichuan University ( Site 3308)
Chengdu, Sichuan, 610047, China
-
Wuhan Union hospital Cancer Center ( Site 3307)
Wuhan, Hubei, 430000, China
-
Xiangya Hospital of Central South University ( Site 3305)
Changsha, Hunan, 410008, China
-
Zhejiang Cancer Hospital ( Site 3303)
Hangzhou, Zhejiang, 310022, China
Conditions
Explore the condition pages connected to this study.